FIELD: medicine.
SUBSTANCE: group of inventions can be used for treating or preventing primary biliary cholangitis in a patient. For this purpose, in the manufacture of a medicament, compound 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid. Said compound is administered in dose of 10 mcg. Also disclosed are application of said agent in doses of 30 mcg, 60 mcg, 90 mcg, 100 mcg.
EFFECT: group of inventions provides treating, as well as preventing primary biliary cholangitis in a patient.
5 cl, 5 tbl, 2 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FXR AGONISTS APPLICATION METHODS | 2017 |
|
RU2743075C2 |
| TREATMENT OF INTRAHEPATIC CHOLESTATIC DISEASES | 2017 |
|
RU2765460C2 |
| METHODS FOR INCREASING HEIGHT OF PEDIATRIC PATIENTS WITH CHOLESTATIC LIVER DISEASE | 2020 |
|
RU2822484C2 |
| DEUTERATED DERIVATIVE OF CHENODEOXYCHOLIC ACID AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND | 2016 |
|
RU2712033C2 |
| METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | 2013 |
|
RU2675514C2 |
| TREATMENT OF CHOLESTATIC ITCHING | 2018 |
|
RU2781281C2 |
| CRYSTALLINE OR AMORPHOUS FORM OF FXR AGONISTS BEING STEROID DERIVATIVES, THEIR PRODUCTION METHOD AND THEIR USE | 2018 |
|
RU2800751C2 |
| PARALYTIC SHELLFISH POISON | 2013 |
|
RU2633637C2 |
| NOVEL PHARMACEUTICAL USE OF THIENO[3,2-D]PYRIMIDIN-4-ONE COMPOUNDS | 2019 |
|
RU2768828C1 |
| COMBINED THERAPY WITH APPLICATION OF CENICRIVIROC FOR FIBROSIS TREATMENT | 2015 |
|
RU2723559C2 |
